Fluorine-18-fluorocyclopropylhexadecanoic acid

Drug Profile

Fluorine-18-fluorocyclopropylhexadecanoic acid

Alternative Names: 18F-FCPHA; 18F-fluorocyclopropylhexadecanoic acid; Cardiac PET imaging agent - FluoroPharma; CardioPET; FCPHA; Fluorocyclopropylhexadecanoic acid-F-18; trans-9-18F-Fluoro-3,4-methylenehepadecanoic acid

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Harvard Medical School; Massachusetts General Hospital
  • Developer FluoroPharma
  • Class Fatty acids; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Coronary artery disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Coronary artery disease(Diagnosis) in USA (IV, Injection)
  • 31 Mar 2017 FluoroPharma has patent protection for the composition and method of use of 18-F FCPHA and 18-F FTPP technologies
  • 06 Jun 2016 Fluorine-18-fluorocyclopropylhexadecanoic acid licensed to Hainan Sinotau Pharmaceutical in China and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top